Paul Atkinson and Sally Sheard say the decision reflects a cautious and evidence-based approach that protects patients and public funds Events
Drugs that slow progression of Alzheimer’s don’t provide enough benefit to justify substantial cost for NHS, regulator has said Events
Scientists and doctors remain divided on the targeted antibody drugs that slow down the early stages of Alzheimer’s Events
Two drugs – donanemab and lecanemab – have been rejected for NHS use because their benefits are "too small" to justify their cost Events
Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s. Events
